PCSK9 and pachyonychia congenita: The current study provides comprehensive evidence for the role of PCSK9 in PC pathogenesis as well as the lead validation of PS as a potent recurrence-suppressing entity for the more aggressive and metastatic type II ADI PC represented by CWR-R1ca [39] by targeting the PCSK9-LDLR axis.